The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using dynamic contrast-enhanced MRI and diffusion weighted MRI: MARBLE study.
 
Rachel Anne Pearson
No Relationships to Disclose
 
Pete E Thelwall
No Relationships to Disclose
 
Jim Snell
No Relationships to Disclose
 
Jill McKenna
No Relationships to Disclose
 
Piotr Pieniazek
No Relationships to Disclose
 
Emily Louise Fitzgerald
No Relationships to Disclose
 
Rakesh Heer
No Relationships to Disclose
 
Rhona Margaret McMenemin
No Relationships to Disclose
 
Ian D. Pedley
No Relationships to Disclose
 
Ashraf S. Azzabi
No Relationships to Disclose
 
Herbie Newell
No Relationships to Disclose
 
Ross J. Maxwell
No Relationships to Disclose
 
Elizabeth R. Plummer
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Biomarin; Clovis Oncology; GlaxoSmithKline; MSD Oncology; Roche/Genentech; Tesaro; Vertex
Research Funding - AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); Eisai (Inst); Etherapeutics (Inst); Ipsen (Inst); vertex (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Roche/Genentech
 
John A. Frew
No Relationships to Disclose